(MENAFN- Straits Research) Bone morphogenetic proteins (BMPs) are a category of cytokines crucial in regulating and promoting bone and cartilage maintenance and development. Bone morphogenetic proteins (BMPs) belong to the beta-super glycoprotein superfamily. Spinal infusion therapy is a beneficial treatment modality that finds application in diverse orthopedic contexts, such as spinal fusions and oral surgery. Rh-BMP-7, also known as recombinant human bone morphogenetic protein-7, is utilized to treat renal disease.
Market Dynamics
Increasing Incidence of Spinal Injuries and the Elderly Population Drives the Global Market
The projected growth of the spinal injury market in the forthcoming years can be attributed to the escalating prevalence of spinal injuries and an accompanying surge in surgical interventions. Numerous manufacturing enterprises are currently engaged in continuous research investigating the therapeutic efficacy of bone morphogenetic proteins (BMP) in diverse orthopedic ailments, including soft tissue regeneration and osteoarthritis. It is anticipated that this research will increase the demand for the product.
Furthermore, the market is expected to experience growth over the forecast period due to various factors, such as the rising prevalence of spinal injuries, sedentary lifestyles, injuries related to sports activities, and suboptimal posture. In order to effectively cater to the needs of the elderly population afflicted with spinal injuries, rehabilitation services, and long-term care facilities must adapt their approach by providing tailored and comprehensive care.
Rising Technological Development Creates Tremendous Opportunities
Improved BMP treatment delivery strategies have been made possible by technological advancements. These developments make it possible to administer BMPs in a more precise and controlled manner, ensuring that they are delivered specifically to the location where they are required. For instance, scientists have developed biocompatible scaffolds, hydrogels, nanoparticles, and microencapsulation methods that enable the slow and targeted release of BMPs. By providing favorable conditions for cell growth and differentiation that closely resembles native tissues, these delivery tools improve the regenerative capacity of BMPs.
Regional Analysis
North America is the most significant global bone morphogenetic protein market shareholder and is predicted to rise significantly during the forecast period. The healthcare system in North America is well-developed and includes world-class hospitals, clinics, and research facilities. The adoption and application of cutting-edge medical technologies like Bone Morphogenetic Protein (BMP) treatments are supported by this robust infrastructure. The region's BMP market is expanding due to the availability of highly qualified healthcare experts and access to cutting-edge facilities.
Additionally, North America's aging population is growing, which contributes to an increase in the prevalence of age-related bone diseases and conditions. BMP therapies are essential for the treatment of older people because they are more prone to fractures and degenerative bone disorders. This demographic trend is driving North America's BMP market growth.
Key Highlights The global bone morphogenetic protein market was valued at USD 459.09 million in 2022. It is estimated to reach USD 607.78 million by 2031, growing at a CAGR of 3.6% during the forecast period (2023–2031). Based on the type, the global bone morphogenetic protein market is divided into rhBMP-2 and rhBMP-7. The rhBMP-2 protein segment is the highest contributor to the market share and is expected to grow significantly over the forecast period. Based on the application, the global bone morphogenetic protein market is divided into spinal fusion, trauma, reconstructive surgery, oral-maxillofacial, and others. The spinal fusion segment owns the highest market share and is expected to grow significantly over the forecast period. North America is the most significant global bone morphogenetic protein market shareholder and is predicted to rise significantly during the forecast period.
Competitive Players
The key players in the Bone Morphogenetic Protein market are Medtronic, Stryker Corporation, Merck KGaA, Prospec-Tany Technogene Ltd, Ember Therapeutics, Thermo Fisher Scientific, Akron Biotechnology LLC, Sino Biological Inc, Integra Lifesciences Holdings Corporation, Zimmer Biomet Holdings, Inc.
Global Bone Morphogenetic Protein Market: Segmentation
By Type Recombinant Human Bone Morphogenetic Protein (rhBMP)-2 Recombinant Human Bone Morphogenetic Protein (rhBMP)-7
By Applications Spinal Fusion Trauma Reconstructive Surgery Oral-Maxillofacial Others
By Regions North America Europe Asia-Pacific Latin America The Middle East and Africa
MENAFN17082023004597010339ID1106878044
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.